Newsletter Subscribe
Enter your email address below and subscribe to our newsletter
Research & Studies
Share your love
Ashvattha reports positive phase 2 results for migaldendranib in DME and nAMD
(Image Credit: AdobeStock) Ashvattha Therapeutics shared positive topline data from its phase 2 study of migaldendranib (MGB) for the treatment of diabetic macular edema (DME) and neovascular age-related macular degeneration (nAMD). The topline end-of-study results were announced at the 25th…
Contivue port delivery platform for nAMD receives CE mark
(Image credit: ©Symbiot/AdobeStock) The European Union has granted the EU CE mark to Roche’s port delivery platform, Contivue.1 This platform contains Susvimo (ranibizumab injection) 100 mg/mL, which is currently under review with the European Medicines Agency (EMA) for the treatment…
Creation of OpZira Inc. announced following Alcon’s acquisition of LumiThera
(Image credit: AdobeStock) The company OpZira Inc. has launched to advance ophthalmic diagnostics. The company plans to deliver innovative technologies with the ability to enhance the detection and monitoring of ocular disease, which can empower clinicians. Clark Tedford, PhD, President…
VirtuaLens launches virtual reality tool: Immersive IOL Simulator
(Image credit: AdobeStock/DeepView) VirtuaLens has launched its Immersive IOL Simulator. This is a virtual reality (VR) platform that is designed to allow cataract patients to explore and compare different intraocular lens (IOL) options before surgery. The company notes that the…
Sight Science’s TearCare System earns spot in TFOS DEWS III dry eye report
(Image Credit: AdobeStock/tadamichi) Sight Sciences announced that its TearCare System has been included in the new Dry Eye Workshop (DEWS) III report from the Tear Film and Ocular Surface Society (TFOS) published in the American Journal of Ophthalmology.1,2 This marks the…
Ophthalmic Devices Market Surges to USD 100.2 Billion by 2033, Propelled by 6.4% CAGR
\n \n The Ophthalmic Devices Market is witnessing robust expansion driven by rising demand for advanced eye care solutions, growing prevalence of vision disorders, and a rapidly aging population. Technological advancements such as AI-driven diagnostics, minimally invasive surgical systems, and…
Outlook Therapeutics requests Type A meeting with FDA following second CRL for ONS-5010
(Image Credit: AdobeStock) Outlook Therapeutics has requested a Type A meeting with the US Food and Drug Administration following the agency issuing a complete response letter (CRL) to its biologics license application (BLA) resubmission for ONS-5010 (bevacizumab-vikg) for the treatment…
Treating ophthalmic artery stenosis in geographic atrophy with angioplasty
(Image credit: AdobeStock/Rina) A study that evaluated the safety and feasibility of treating ophthalmic artery stenoses with angioplasty in patients with late-stage age-related macular degeneration (AMD) with geographic atrophy (GA) showed reported observing efficacy and functional improvement in this patient…
The state of retina at ASRS 2025 with Charles C. Wykoff, MD, PhD, and Kevin Quinn
(Image credit: AdobeStock/vetrana) The annual scientific meeting of the American Society of Retina Specialists (ASRS) was held in Long Beach, California from July 30 through August 2, 2025. At this event, researchers and experts in the retina field shared data…
EyeCool Therapeutics appoints Vance Thompson, MD, to board of directors
EyeCool Therapeutics has appointed Vance Thompson, MD, founder of Vance Thompson Vision and immediate past president of the American Society of Cataract and Refractive Surgery (ASCRS), to the company’s board of directors. Thompson has personally performed more than 100,000 vision…